Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the myasthenia gravis treatment market grown in recent years?

Over the past few years, the myasthenia gravis treatment market has seen vigorous growth. It’s projected to expand from a value of $1.55 billion in 2024 to $1.66 billion in 2025, representing a compound annual growth rate (CAGR) of 7.3%. The surge in market growth can be ascribed to factors like the introduction of cholinesterase inhibitors, advancements in thymectomy procedures, the rise of immunosuppressive therapies, the initiation of plasma exchange, and increased patient advocacy efforts.

How is the myasthenia gravis treatment market size expected to evolve during the forecast period?

In the coming years, the market size for myasthenia gravis treatment is projected to experience robust growth, expanding to $2.26 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.0%. This growth within the projected period can be linked to advancements such as biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Key trends during this forecast period encompass digital therapeutics, joint research efforts, a focus on patient-centered approaches, the use of real-world evidence, and continuous safety monitoring.

Get your myasthenia gravis treatment market report here!

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Which key drivers are propelling the myasthenia gravis treatment market’s growth?

The upward trend in myasthenia gravis cases is anticipated to stimulate the expansion of the market for its treatment. Myasthenia gravis is an autoimmune neuromuscular disease that leads to fatigue and weakness in the patients’ skeletal muscles. The treatment of myasthenia gravis involves offering medical services and care to counteract the illness. Therefore, the rise in cases of myasthenia gravis is fostering growth in the market for its treatment. For instance, data released in January 2022 by the National Organization for Rare Disorders, a non-profit organization from the US aiding people with rare diseases, it was estimated that autoimmune myasthenia gravis had a prevalence rate ranging from 14 to 40 per 100,000 individuals in the United States. Moreover, a report from the American Journal of Managed Care, a US-based peer-reviewed journal, published in April 2024, indicated an annual incidence rate of 4.32 cases per 100,000 individuals based on an average of 1,800 diagnoses of myasthenia gravis annually. This report also estimated a rate of 2.46 cases per 100,000 person-years. Thus, the escalating incidence of myasthenia gravis is fueling the expansion of the market for its treatment.

What are the market segments in the myasthenia gravis treatment industry?

The myasthenia gravis treatment market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types

3) By End-Use: Hospitals, Clinics, Other End-Uses

Subsegments:

1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids

2) By Surgery: Thymectomy

3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

Which leading companies are shaping the growth of the myasthenia gravis treatment market?

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

What key trends are currently impacting the myasthenia gravis treatment market’s development?

In the treatment market for myasthenia gravis, a critical trend that is gaining ground is the invention of new products. The focus of big-name companies in this market is to create innovative solutions to hold their market place. For example, in October 2023, the FDA of the United States approved a drug called Zilucoplan, announced by UCB Pharma, a pharmaceutical company from Belgium. The drug is prescribed to adults suffering from generalized myasthenia gravis (gMG) confirmed as anti-acetylcholine receptor (AChR) antibodies positive. The approval of this drug introduces another approach to gMG management, a disorder characterized by an autoimmune response causing muscle weakness. ZILBRYSQ stands out as being a complement C5 inhibitor that is self-administered subcutaneously once a day, providing a more comfortable substitute for the typical intravenous therapies that have become the norm for gMG treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11980

Which geographic areas are influencing the growth of the myasthenia gravis treatment market?

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Print Advertising Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/print-advertising-global-market-report

Printing Machinery And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/printing-machinery-and-equipment-global-market-report

Printer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/printer-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: